Drugs Losing Exclusivity in 2028 & Key Intermediates
18 drugs expire in 2028 (public sources), 18 with recorded synthesis routes; key intermediates of 13 drugs are already available through the Unibest supply network. Generic developers typically secure intermediate supply 2–3 years ahead — use this table for shortlisting and RFQ.
| Drug | Tier | Expiry | Indications | Routes | CAS count | Available |
|---|---|---|---|---|---|---|
| Tofacitinib Citrate | B · Position early | 2028 | Ankylosing spondylitis, Juvenile rheumatoid arthritis, Ulcerative colitis | 7 | 34 | Available ×34 |
| Roxadustat | C · Watch | 2028 | Anaemia | 3 | 33 | Available ×33 |
| Apixaban | A · Act now | 2028 | Pulmonary embolism, Venous thrombosis, Paget-Schroetter syndrome | 7 | 30 | Available ×30 |
| Brivaracetam | C · Watch | 2028 | Partial-onset seizure, Epilepsy, Seizure | 3 | 26 | Available ×26 |
| Empagliflozin | A · Act now | 2028 | Chronic renal impairment, Heart failure, Type 2 diabetes | 3 | 24 | Available ×24 |
| Ruxolitinib Phosphate | A · Act now | 2028 | Atopic dermatitis, Vitiligo, Graft-versus-host disease | 4 | 24 | Available ×24 |
| Lenvatinib Mesilate | A · Act now | 2028 | Renal cell carcinoma, Endometrial cancer, Hepatocellular carcinoma | 3 | 18 | Available ×18 |
| Olaparib | A · Act now | 2028 | Endometrial cancer, Castration-resistant prostate cancer, Prostate cancer | 2 | 13 | Available ×13 |
| Edoxaban Tosilate Hydrate | B · Position early | 2028 | Pulmonary embolism, Venous thromboembolism, Stroke | 6 | 37 | Available ×4 |
| Lurasidone Hydrochloride | B · Position early | 2028 | Major depressive disorder, Schizophrenia, Mania | 6 | 20 | Available ×4 |
| Avanafil | C · Watch | 2028 | Erectile dysfunction | 7 | 35 | Available ×4 |
| Lacosamide | B · Position early | 2028 | Tonic-clonic seizure, Epilepsy, Partial-onset seizure | 7 | 35 | Available ×3 |
| Perampanel Hydrate | C · Watch | 2028 | Tonic-clonic seizure, Partial-onset seizure, Epilepsy | 5 | 34 | Available ×1 |
| Apremilast | B · Position early | 2028 | Plaque psoriasis, Behçet's syndrome, Oral ulcer | 6 | 25 | - |
| Sugammadex Sodium | B · Position early | 2028 | Neuromuscular blockade | 1 | - | - |
| Tolvaptan | B · Position early | 2028 | Autosomal dominant polycystic kidney disease, Fibrosis, Hyponatraemia | 6 | 28 | - |
| Betrixaban | C · Watch | 2028 | Venous thromboembolism, Hepatic function decline, Atrial fibrillation | 2 | 10 | - |
| Fidaxomicin | C · Watch | 2028 | Clostridioides difficile infection, Enteritis, Diarrhoea | 1 | - | - |
Frequently asked questions
Which drugs lose exclusivity in 2028?
18 drugs expire in 2028 per public sources: Apixaban, Empagliflozin, Tofacitinib Citrate, Apremilast, Ruxolitinib Phosphate, Olaparib, etc.
When should we start sourcing intermediates for 2028 launches?
Generic developers typically secure development-scale supply 2–3 years before expiry. 13 of the 18 drugs in this table already have on-sale intermediates in the Unibest network; the rest can be RFQ'd per CAS.
Are route and CAS data verified?
All fields are structured data cross-verified from public sources; intermediates carry registry codes and CAS numbers, and every "Available" badge links to real listings.
Source: cross-verified structured fields · Expiry years are public-source estimates; consult individual agencies for authoritative dates · 2026-09-29